How harmful industries shape health science and law
Tobacco, ultra-processed food, fossil fuels and alcohol are linked to about a third of deaths worldwide. Court rulings and internal documents show how some of their makers funded science and fought rules to protect sales.
How this affects people
Noncommunicable diseases such as heart disease, cancer, diabetes and lung disease killed at least 43 million people in 2021, three in four deaths not caused by the pandemic, and 18 million of them before age 70. In Europe alone, WHO links about 2.7 million deaths a year, some 7,400 a day, to tobacco, alcohol, unhealthy food, fossil fuels and workplace hazards. Up to about 45% of dementia cases could in theory be prevented or delayed; smoking, heavy drinking, obesity, diabetes and air pollution are among its 14 risk factors.
The methods are on the record. In 1965 the sugar industry paid two Harvard scientists US$6,500 (US$48,900 in 2016 dollars) for a review that played down sugar and blamed fat, and the funding was not disclosed. In 2006 a US federal judge ruled that the major cigarette makers had deceived the public about smoking for more than 50 years, in violation of racketeering law. A 2018 study traced 389 articles citing Coca-Cola funding, much of it stressing exercise over diet. In the US, the ultra-processed food, tobacco and alcohol industries spent about US$2.4 billion on federal lobbying from 1998 to 2020.
Look at what keeps the problem going
- 01Profits that depend on selling more of a harmful product
- 02Industry-funded research that casts doubt or shifts the blame
- 03Lobbying and legal challenges against health rules
- 04Marketing aimed at young and vulnerable people
What could happen next
The future leaves room for choices. Compare the outlooks, check what supports them and notice where the evidence becomes less certain
Every health rule draws lobbying
WHO Europe documents lobbying, misleading claims and targeted marketing wherever taxes, labels or marketing limits are proposed.
The future is not a timetable. These summaries reflect published scenarios and trends, with deeper uncertainty at longer horizons. Choices made now matter.
Where could a useful response begin?
Begin with a question you can investigate. Compare the sources and follow related briefings to see how the problem connects to other lives and places. This prototype does not accept proposals yet.
This preview does not accept proposals or create an account.
Sources
- Defining and conceptualising the commercial determinants of healthThe Lancet · 2023
- Commercial determinants of noncommunicable diseases in the WHO European RegionWHO Regional Office for Europe · 2024
- Noncommunicable diseasesWorld Health Organization · 2025
- Sugar Industry and Coronary Heart Disease Research: A Historical Analysis of Internal Industry DocumentsJAMA Internal Medicine · 2016
- Coca-Cola – a model of transparency in research partnerships? A network analysis of Coca-Cola's research funding (2008–2016)Public Health Nutrition · 2018
- United States v. Philip Morris USA Inc. et al.: case page with the 2006 final opinion and order (page updated 2014)US Department of Justice, Civil Division · 2014
- Mapping the Lobbying Footprint of Harmful Industries: 23 Years of Data From OpenSecretsThe Milbank Quarterly · 2024
- Dementia prevention, intervention, and care: 2024 report of the Lancet standing CommissionThe Lancet · 2024
- DementiaWorld Health Organization · 2026